• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Financial Officer Goldstein Dov A Md

    2/20/25 4:19:02 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    GOLDSTEIN DOV A MD

    (Last) (First) (Middle)
    C/O BIOAGE LABS, INC.
    1445A SOUTH 50TH STREET

    (Street)
    RICHMOND CA 94804

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BioAge Labs, Inc. [ BIOA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    02/18/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $4.38 02/18/2025 A 170,000 (1) 02/17/2035 Common Stock 170,000 $0 170,000 D
    Explanation of Responses:
    1. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
    /s/ Dov A. Goldstein 02/20/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BIOA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOA

    DatePrice TargetRatingAnalyst
    2/28/2025Mkt Perform
    William Blair
    12/10/2024$40.00 → $5.00Overweight → Underweight
    Morgan Stanley
    12/9/2024$42.00 → $7.00Buy → Hold
    Jefferies
    12/9/2024$45.00 → $7.00Buy → Neutral
    Citigroup
    10/21/2024$45.00Buy
    Citigroup
    10/21/2024$42.00Buy
    Jefferies
    10/21/2024$40.00Overweight
    Morgan Stanley
    More analyst ratings

    $BIOA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

      4/A - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:11:28 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

      4 - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:10:37 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Pande Vijay Satyanand bought $4,329,019 worth of shares (219,195 units at $19.75) (SEC Form 4)

      4 - BioAge Labs, Inc. (0001709941) (Issuer)

      10/3/24 7:19:49 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

      Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic collaboration with Lilly ExploR&D expands therapeutic approach to novel metabolic aging targetsProgression of preclinical next-generation APJ agonists for obesity RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided business updates and reported its first quarter 2025 financial results. "The first quarter of 2025 was marke

      5/6/25 4:30:00 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

      Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and Lilly to discover and develop novel therapies for conditions driven by metabolic aging RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2024 and business updates for the fourth quarter ended Decembe

      3/20/25 4:30:00 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioArctic receives Orphan Drug Designation for exidavnemab the US

      STOCKHOLM, March 17, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need. Multiple System Atrophy (MSA) is a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems. MSA is characterized by pathological alpha-synuclein aggregation, that causes gradual damage to nerve cells in the brain. This affects balance, movement and the autonomic nervous system, which

      3/17/25 1:49:00 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

      4/A - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:11:28 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

      4 - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:10:37 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Chief Operating Officer Morgen Eric

      4/A - BioAge Labs, Inc. (0001709941) (Issuer)

      2/25/25 4:28:11 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    SEC Filings

    See more
    • SEC Form 10-Q filed by BioAge Labs Inc.

      10-Q - BioAge Labs, Inc. (0001709941) (Filer)

      5/6/25 4:40:22 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BioAge Labs, Inc. (0001709941) (Filer)

      5/6/25 4:35:09 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by BioAge Labs Inc.

      DEFA14A - BioAge Labs, Inc. (0001709941) (Filer)

      4/17/25 4:10:03 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioAge Labs Inc.

      SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

      11/14/24 4:15:56 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by BioAge Labs Inc.

      SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

      11/12/24 4:15:53 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by BioAge Labs Inc.

      SC 13D - BioAge Labs, Inc. (0001709941) (Subject)

      10/4/24 8:21:35 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on BioAge Labs

      William Blair initiated coverage of BioAge Labs with a rating of Mkt Perform

      2/28/25 7:20:24 AM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded BioAge Labs from Overweight to Underweight and set a new price target of $5.00 from $40.00 previously

      12/10/24 7:54:08 AM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs downgraded by Jefferies with a new price target

      Jefferies downgraded BioAge Labs from Buy to Hold and set a new price target of $7.00 from $42.00 previously

      12/9/24 7:29:20 AM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care